相关实验视频
Updated: May 7, 2026
05:51
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
13.3K
动脉样硬化中的表观基因-ncRNA交叉声调:机制,疾病进展和治疗潜力 (综述)
Ying Zhu1, Zhixin Hu2, Jianshuo Liu3
1Department of Blood Transfusion, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China.
International journal of molecular medicine
|September 5, 2025
概括
表观遗传修饰和非编码RNAs (ncRNAs) 显著影响动脉样硬化进展. 针对这些途径为心血管疾病提供了潜在的治疗策略.
科学领域:
- 心血管生物学
- 分子医学
- 表观遗传学
背景情况:
- 动脉样硬化是一种慢性血管疾病,其特征是动脉壁变厚,血液流量受限,增加心肌梗塞和中风的风险.
- 表观遗传修饰和非编码RNAs (ncRNAs) 越来越多地被认为是动脉样硬化的关键调节者.
- 这些分子机制调节关键过程,包括内皮功能障碍,脂质代谢和炎症.
研究的目的:
- 探索表观遗传调节剂和ncRNAs在动脉样硬化的发展和进展中的复杂作用.
- 突出显示血管疾病中的基因组修饰,DNA甲基化和各种ncRNA类之间的相互作用.
- 确定这些表观遗传和ncRNA途径中的潜在治疗点,以治疗动脉样硬化.
主要方法:
- 对最近的科学文献进行审查,重点是动脉样硬化中的表观遗传机制 (基因组修饰,DNA甲基化) 和ncRNA (miRNA,LncRNA,circRNA).
- 对DNMT和HDAC等表观遗传调节剂如何影响血管基因表达的分析.
- 检查ncRNA在调节胆固醇外流和泡细胞形成等细胞过程中的功能.
主要成果:
- 表观遗传修饰和ncRNA是动脉样硬化的分子组成部分.
- 特定的表观遗传调节剂和ncRNA直接影响内皮功能,脂质处理和炎症反应.
- 这些元素之间的复杂相互作用会导致疾病的进展.
结论:
- 了解表观遗传和ncRNA调节网络为动脉样硬化提供了新的治疗途径.
- 表观遗传变化的可逆性和基于ncRNA的疗法的潜力为未来的临床应用提供了希望.
- 需要进一步的研究来解决基于ncRNA的有效干预的交付和特异性方面的挑战.
相关概念视频
01:17Ischemic Heart Disease: Overview
3.9K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.9K
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
1.3K
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.3K
01:21Rheumatic Heart Disease III: Medical Management
548
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
548
01:26Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
961
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
961
01:26Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747